invited speakers
MICHAEL HALLER
Dr. Michael Haller is a pediatric endocrinologist with a passion for patient care, teaching, and research. Mike is a Gainesville native and a proud graduate of the University of Florida’s College of Medicine, Pediatrics Residency, and Pediatric Endocrinology Fellowship Programs. In addition to serving as the Pediatric Endocrinology Chief and Fellowship director, Dr. Haller coordinates an active research team focused on the prediction, prevention, and reversal of type 1 diabetes.
Dr. Haller is an active investigator in the NIH funded Type 1 Diabetes TrialNet, the NIH TEDDY study, and the T1D Exchange. Mike serves as the Co-PI of the University of Florida TrialNet Clinical Center, as the Chair of the Clinical Implementation Committee for the TEDDY study, and as Vice-President of the Florida Camp for Children and Youth with Diabetes. Dr. Haller was the PI of “first in man” studies aimed at using autologous umbilical cord blood stem cells as a potential therapy for type 1 diabetes and more recently led a groundbreaking pilot study demonstrating the efficacy of Thymogloublin and Neulasta in patients with established type 1 diabetes. Dr. Haller now serves as the PI of a major TrialNet study aimed at confirming the efficacy of Thymoglobulin and Neulasta in new-onset type 1 diabetes patients.
ERIK IMEL
Erik Imel, M.S., M.D. is an Associate Professor of Medicine and Pediatrics at the Indiana University School of Medicine whose clinical and research focus is on bone and mineral disorders, especially rare bone disorders, including X-linked hypophosphatemia. His unique background includes dual training and certification in both Adult Endocrinology and Pediatric Endocrinology at the Indiana University School of Medicine.
Dr. Imel is also an Affiliate Scientist of the Regenstrief Institute’s Center for Biomedical Informatics and the Associate Core Director for the Indiana Center for Musculoskeletal Health-Clinical Research Core, conducting and facilitating biomedical informatics studies of musculoskeletal outcomes, using large multi-institution electronic health databases. He has conducted important clinical and translational research in both rare and common musculoskeletal diseases, including clinical trials in X-linked hypophosphatemia (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal dominant osteopetrosis (ADO2), as well as osteoporosis. In particular, he has been a leading investigator at the forefront of multicenter phase I, II, III and IV clinical trials of burosumab (an anti-FGF23 antibody), leading to its regulatory approval for both children and adults with XLH. Dr. Imel’s clinical and research efforts are directed towards decreasing the burden and consequences of musculoskeletal disorders at all ages.
MICHEL POLAK
His training took place in Paris and during postdoctoral fellowships in the Department of genetics and microbiology, Centre Médical Universitaire, Genève, Switzerland (1997) and at Harvard Medical School, Department of Neurobiology (Pr Potter) and Section of Immunology and Immunogenetics, Elliot P. Joslin Research Laboratory (Pr Eisenbarth), Joslin Diabetes Center, Boston, MA, USA (1989-1991).
He has published more than 220 peer-reviewed papers in his field and was offered in 2003 the Jacques Raymond Ducharme award in pediatric endocrinology of the Sainte Justine hospital, Montréal, Canada and in 2006 a French national award in medicine: “les victoires de la médecine” for the work on neonatal diabetes mellitus. Pr Polak received the prestigious “European Society for Pediatric Endocrinology research award” in 2012 for his work.
CONTACT
APEG Conference Secretariat
PO Box 180 Morisset NSW 2264 Australia
+61 2 4973 6573